Generated by AI
Personalis, Inc. is a genomic diagnostics and data-analysis company focused on precision oncology and population genomics. Its current offerings include advanced sequencing tests that characterize tumors and immune-system interactions, supporting cancer diagnosis, treatment selection, disease monitoring, and pharmaceutical research. The company provides products such as ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which are designed to generate detailed genomic and immunologic insights from patient samples. Personalis, Inc. also delivers sequencing and analytical services for biopharmaceutical organizations developing cancer therapies, including personalized vaccines and immunotherapies, as well as for large-scale population sequencing initiatives. Its capabilities combine laboratory testing, bioinformatics, and data interpretation to help researchers and healthcare professionals understand disease biology and treatment response. Headquartered in Fremont, California, Personalis, Inc. serves the growing precision-medicine market by connecting high-resolution genomic information with clinical and drug-development applications.
Website6600 Dumbarton Circle
Fremont, CA, 94555
United States
The latest articles about PSNL.
Personalis reported third quarter 2026 sales of US$25.6 million and a net loss of US$33.8 million, with basic loss per share from continuing operations of US$0.32. For the nine month period, the company reported sales of US$63.43 million and a net loss of US$95.52 million, or US$0.90 per share. The earnings update showed higher top line figures alongside wider losses, which highlights ongoing cost intensity and execution pressure as Personalis scales its cancer genomics business. We will...
Summary of Aug 25's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
Summary of Jul 20's posts. Generated by AI.
Summary of Aug 20's posts. Generated by AI.
Investors talking about PSNL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.